»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China Cediranib CAS 288383-20-0 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quina manufacturer

5th

Gold Index: 89140

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > Cediranib CAS 288383-20-0 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quina

Cediranib CAS 288383-20-0 4-(4-Fluoro-2-methylindol-5-yloxy)-6-methoxy-7-[3-(pyrrolidin-1-yl)propoxy]quina 

Payment Terms: T/T,L/C,WU 
Place of Origin: Sichuan, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Model No.: C25H27FN4O3
Production Capacity: 20T/Year
Delivery Date: within 7 days
Appearance: Yellowish crystalline powde...
Mol. mass: 450.505 g/mol
Boiling point: 626.557°C at 760 mmHg
Vapour pressure: 0mmHg at 25°C
Means of Transport: Ocean,Land,Air
Packing: According to customer requi...
Brand: MOSINTER
Formula: C25H27FN4O3
Density: 1.286g/cm
Flash(ing) point: 332.73°C
Alias: 4-(4-Fluoro-2-methylindol-5...

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

Cediranib (CAS: 288383-20-0)


Item

Index

Molecular Formula

C25H27FN4O3

Molecular Weight

450.51

Specification

CP/USP/EP

Content

≥98.0%

Appearance

Cediranib is a yellowish crystalline powder.

Properties

Cediranib is a potent inhibitor of vascular endothelial growth factor (VEGF) receptor tyrosine kinases.

The drug is being developed by AstraZeneca as a possible anti-cancer chemotherapeutic agent for oral administration.

Beginning in 2007, it underwent Phase I clinical trials for the treatment of non-small cell lung cancer, kidney cancer, and colorectal cancer in adults, as well as tumors of the central nervous system in children. Phase I trials of interactions with other drugs used in cancer treatment were also undertaken.

On February 27, 2008, AstraZeneca announced that the use of Cediranib in non-small cell lung cancer will not progress into phase III after failing to meet its main goal. On 8 March 2010, AstraZeneca issued a press-release stating that Cediranib had failed Phase III clinical trials for use in first-line metastatic colorectal cancer when it was compared clinically with the market-leader bevacizumab. As of November 2012, it was being assessed in double-blind studies for the treatment of methylated Glioblastoma Multiforme at the University of Washington Medical Center at a 20 mg daily dose.

Combination Trials

Findings from a federally funded, NCI-sponsored phase II clinical trial presented at the 50th Annual Meeting of the American Society of Clinical Oncology (May 30 - June 3, 2014, Chicago, Ill; Abstract No: LBA5500), show that the combination of two investigational oral drugs, olaparib (AZD-2281; AstraZeneca) , a potential first-in-class poly ADP ribose polymerase or PARP inhibitor and cediranib, an anti-angiogenesis drug, is significantly more active against recurrent, platinum chemotherapy-sensitive disease or ovarian cancer related to mutations in BRCA genes than olaparib alone.

Hazards Identification 

Adverse Effects: Adverse effects of vaginal application may include vaginal burning, itching, 

discharge or other irritation;abdominal cramps or pain; and headache. Possible allergic 

reaction to material if inhaled, ingested or in contact with skin. 

Overdose Effects: n/f 

Acute: Possible eye, skin, gastrointestinal and/or respiratory tract irritation. 

Chronic: Possible hypersensitization. 

Inhalation: May cause irritation. Remove to fresh air. 

Eye: May cause irritation. Flush with copious quantities of water. 

Skin: May cause irritation. Flush with copious quantities of water. 

Ingestion: May cause irritation. Flush out mouth with water. 

Medical Conditions Aggravated by Exposure: Hypersensitivity to material. 

Cross Sensitivity: Persons sensitive to azole antifungal agents may be sensitive to this material 

also. 

Pregnancy Comments: Adequate and well-controlled pregnancy studies in humans have not 

been done. In studies in rats, adverse effects on fetal development and delivery were observed 

during local and systemic use. 

Pregnancy Category: C


bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: